The Immune Microenviroment in Somatotropinomas: from Biology to Personalized and Target Therapy

Overview

Journal Rev Endocr Metab Disord

Publisher Springer

Specialty Endocrinology

Date 2023 Jan 19

PMID 36658300

Authors

Sabrina Chiloiro

Laura De Marinis

Affiliations

Soon will be listed here.

Abstract

Pituitary tumors are rare neoplasms, with a heterogeneous biological and clinical behavior, due to their clinical course, local invasive growth, resistance to conventional therapies and the risk of disease progression. Recent studies on tumor microenvironment (TME) provided new knowledge on the biology of these neoplasia, that may explain the different phenotypes of these tumors and suggest new biomarkers able to predict the prognosis and the treatment outcome. The identification of molecular markers that act as targets for biological therapies may open new perspectives in the medical treatments of aggressive pituitary tumors.In this paper, we will review data of TME and target therapies in somatotropinomas.

Citing Articles

Cancer screening in patients with acromegaly: a plea for a personalized approach and international registries.

Demarchis L, Chiloiro S, Giampietro A, De Marinis L, Bianchi A, Fleseriu M Rev Endocr Metab Disord. 2025; .

PMID: 40088375 DOI: 10.1007/s11154-025-09957-6.

Cytokines and chemokines modulate the growth of pituitary adenoma/neuroendocrine tumors: preliminary results of a monocenter prospective pilot study.

Chiloiro S, Mattogno P, Angelini F, Giampietro A, Vicari A, Konini G Pituitary. 2025; 28(2):37.

PMID: 40064752 PMC: 11893686. DOI: 10.1007/s11102-025-01505-4.

Flow cytometry immune profiling of recurrent and newly diagnosed growth hormone secreting pituitary neuroendocrine tumors: comparison of two clinical cases.

Lisina D, Mazeeva V, Zakharova E, Sorokina A, Dzhemileva L, Grigoriev A BMC Endocr Disord. 2025; 25(1):37.

PMID: 39939927 PMC: 11816545. DOI: 10.1186/s12902-025-01865-9.

Acromegaly and COVID-19, lessons, and new opportunities.

Varlamov E, Fleseriu M Pituitary. 2024; 27(6):935-944.

PMID: 38819618 DOI: 10.1007/s11102-024-01404-0.

Immunological signatures and predictive biomarkers for first-generation somatostatin receptor ligand resistance in Acromegaly.

Luo M, Yu J, Tang R J Neurooncol. 2024; 167(3):415-425.

PMID: 38441839 DOI: 10.1007/s11060-024-04620-7.

References

Sol B, de Filette J, Awada G, Raeymaeckers S, Aspeslagh S, Andreescu C . Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?. Eur J Endocrinol. 2020; 184(1):K1-K5. PMC: 7707801. DOI: 10.1530/EJE-20-0151. View

Tulipano G, Giustina A . Autophagy in normal pituitary and pituitary tumor cells and its potential role in the actions of somatostatin receptor ligands in acromegaly. Rev Endocr Metab Disord. 2021; 22(2):147-160. DOI: 10.1007/s11154-021-09649-x. View

Lamb L, Sim H, McCormack A . Case Report: A Case of Pituitary Carcinoma Treated With Sequential Dual Immunotherapy and Vascular Endothelial Growth Factor Inhibition Therapy. Front Endocrinol (Lausanne). 2020; 11:576027. PMC: 7708326. DOI: 10.3389/fendo.2020.576027. View

Marques P, de Vries F, Dekkers O, van Furth W, Korbonits M, Biermasz N . Pre-operative serum inflammation-based scores in patients with pituitary adenomas. Pituitary. 2020; 24(3):334-350. DOI: 10.1007/s11102-020-01112-5. View

Kapur G, Patwari A, Narayan S, Anand V . Serum prolactin in celiac disease. J Trop Pediatr. 2004; 50(1):37-40. DOI: 10.1093/tropej/50.1.37. View

Lee M, Wiedemann T, Gross C, Leinhauser I, Roncaroli F, Braren R . Targeting PI3K/mTOR Signaling Displays Potent Antitumor Efficacy against Nonfunctioning Pituitary Adenomas. Clin Cancer Res. 2015; 21(14):3204-15. DOI: 10.1158/1078-0432.CCR-15-0288. View

Chanal M, Chevallier P, Raverot V, Fonteneau G, Lucia K, Monteserin Garcia J . Differential Effects of PI3K and Dual PI3K/mTOR Inhibition in Rat Prolactin-Secreting Pituitary Tumors. Mol Cancer Ther. 2016; 15(6):1261-70. DOI: 10.1158/1535-7163.MCT-15-0891. View

Kemeny H, Elsamadicy A, Farber S, Champion C, Lorrey S, Chongsathidkiet P . Targeting PD-L1 Initiates Effective Antitumor Immunity in a Murine Model of Cushing Disease. Clin Cancer Res. 2019; 26(5):1141-1151. PMC: 7809696. DOI: 10.1158/1078-0432.CCR-18-3486. View

Ilie M, Vasiljevic A, Jouanneau E, Raverot G . Immunotherapy in aggressive pituitary tumors and carcinomas: a systematic review. Endocr Relat Cancer. 2022; 29(7):415-426. DOI: 10.1530/ERC-22-0037. View

10.

Taniguchi-Ponciano K, Andonegui-Elguera S, Pena-Martinez E, Silva-Roman G, Vela-Patino S, Gomez-Apo E . Transcriptome and methylome analysis reveals three cellular origins of pituitary tumors. Sci Rep. 2020; 10(1):19373. PMC: 7652879. DOI: 10.1038/s41598-020-76555-8. View

11.

Lu J, Adam B, Jack A, Lam A, Broad R, Chik C . Immune Cell Infiltrates in Pituitary Adenomas: More Macrophages in Larger Adenomas and More T Cells in Growth Hormone Adenomas. Endocr Pathol. 2015; 26(3):263-72. DOI: 10.1007/s12022-015-9383-6. View

12.

Aboelnaga M, Abdullah N, El Shaer M . 25-hydroxyvitamin D Correlation with Prolactin Levels and Adenoma Size in Female Patients with Newly Diagnosed Prolactin Secreting Adenoma. Endocr Metab Immune Disord Drug Targets. 2017; 17(3):219-225. DOI: 10.2174/1871530317666170609103332. View

13.

Chikanza I . Prolactin and neuroimmunomodulation: in vitro and in vivo observations. Ann N Y Acad Sci. 1999; 876:119-30. DOI: 10.1111/j.1749-6632.1999.tb07629.x. View

14.

Takahashi N, Nishihira J, Sato Y, Kondo M, Ogawa H, Ohshima T . Involvement of macrophage migration inhibitory factor (MIF) in the mechanism of tumor cell growth. Mol Med. 1999; 4(11):707-14. PMC: 2230345. View

15.

Cristina C, Perez-Millan M, Luque G, Dulce R, Sevlever G, Berner S . VEGF and CD31 association in pituitary adenomas. Endocr Pathol. 2010; 21(3):154-60. DOI: 10.1007/s12022-010-9119-6. View

16.

Kosmaczewska A, Ciszak L, Potoczek S, Frydecka I . The significance of Treg cells in defective tumor immunity. Arch Immunol Ther Exp (Warsz). 2008; 56(3):181-91. DOI: 10.1007/s00005-008-0018-1. View

17.

Ilie M, Lasolle H, Raverot G . Emerging and Novel Treatments for Pituitary Tumors. J Clin Med. 2019; 8(8). PMC: 6723109. DOI: 10.3390/jcm8081107. View

18.

Marques P, Barry S, Carlsen E, Collier D, Ronaldson A, Awad S . Pituitary tumour fibroblast-derived cytokines influence tumour aggressiveness. Endocr Relat Cancer. 2019; 26(12):853-865. DOI: 10.1530/ERC-19-0327. View

19.

Iacovazzo D, Chiloiro S, Carlsen E, Bianchi A, Giampietro A, Tartaglione T . Tumour-infiltrating cytotoxic T lymphocytes in somatotroph pituitary neuroendocrine tumours. Endocrine. 2019; 67(3):651-658. PMC: 7054228. DOI: 10.1007/s12020-019-02145-y. View

20.

Marques P, Silva A, Lopez-Presa D, Faria C, Bugalho M . The microenvironment of pituitary adenomas: biological, clinical and therapeutical implications. Pituitary. 2022; 25(3):363-382. DOI: 10.1007/s11102-022-01211-5. View